View ValuationGerresheimer 향후 성장Future 기준 점검 3/6Gerresheimer (는) 각각 연간 42.7% 및 5.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 45.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.2% 로 예상됩니다.핵심 정보42.7%이익 성장률45.92%EPS 성장률Life Sciences 이익 성장20.1%매출 성장률5.1%향후 자기자본이익률8.22%애널리스트 커버리지Good마지막 업데이트10 Jun 2026최근 향후 성장 업데이트공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.공시 • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) IndexValuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).공시 • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.공시 • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026공시 • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.Reported Earnings • Oct 10Second quarter 2025 earnings released: EPS: €0.49 (vs €0.94 in 2Q 2024)Second quarter 2025 results: EPS: €0.49 (down from €0.94 in 2Q 2024). Revenue: €600.7m (up 20% from 2Q 2024). Net income: €17.0m (down 48% from 2Q 2024). Profit margin: 2.8% (down from 6.5% in 2Q 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €30.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €60.49 per share.공시 • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.공시 • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.공시 • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).공시 • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.공시 • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.공시 • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.이익 및 매출 성장 예측BIT:1GXI - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수11/30/20282,680111N/A368711/30/20272,49685553421211/30/20262,37357383021211/30/20252,3093-80209128/31/20252,25023-439254N/A5/31/20252,18863-468239N/A2/28/20252,09079-549185N/A11/30/20242,036110-130240N/A8/31/20242,012114-131256N/A5/31/20242,002115-54344N/A2/29/20241,999117-15371N/A11/30/20231,990116-44294N/A8/31/20231,974107-27287N/A5/31/20231,959107-80205N/A2/28/20231,90497-89171N/A11/30/20221,81796-38222N/A8/31/20221,72591-45214N/A5/31/20221,63482-20225N/A2/28/20221,566854238N/A11/30/20211,498846212N/A8/31/20211,465861203N/A5/31/20211,43293-13182N/A2/28/20211,4189462243N/A11/30/20201,4198948222N/A8/31/20201,385-2553235N/A5/31/20201,394-3226208N/A2/29/20201,388-14-16165N/A11/30/20191,3928128193N/A8/31/20191,4152072161N/A5/31/20191,410207N/A183N/A2/28/20191,386179N/A159N/A11/30/20181,368129N/A173N/A8/31/20181,351124N/A184N/A5/31/20181,329131N/A192N/A2/28/20181,336137N/A206N/A11/30/20171,348101N/A219N/A8/31/20171,33149N/A184N/A5/31/20171,35053N/A176N/A2/28/20171,35856N/A190N/A11/30/20161,37558N/A173N/A8/31/20161,299118N/A195N/A5/31/20161,292106N/A201N/A2/29/20161,30199N/A188N/A11/30/20151,28396N/A204N/A8/31/20151,33569N/A206N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1GXI 의 연간 예상 수익 증가율(42.7%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: 1GXI 의 연간 수익(42.7%)이 Italian 시장(11.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 1GXI 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 1GXI 의 수익(연간 5.1%)이 Italian 시장(연간 5.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 1GXI 의 수익(연간 5.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1GXI의 자본 수익률은 3년 후 8.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 18:07종가2026/06/10 00:00수익2025/08/31연간 수익2024/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gerresheimer AG는 34명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jonathon UnwinBarclaysPallav MittalBarclaysGaurav JainBarclays31명의 분석가 더 보기
공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.
공시 • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.
New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).
공시 • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.
공시 • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026
공시 • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.
Reported Earnings • Oct 10Second quarter 2025 earnings released: EPS: €0.49 (vs €0.94 in 2Q 2024)Second quarter 2025 results: EPS: €0.49 (down from €0.94 in 2Q 2024). Revenue: €600.7m (up 20% from 2Q 2024). Net income: €17.0m (down 48% from 2Q 2024). Profit margin: 2.8% (down from 6.5% in 2Q 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €30.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €60.49 per share.
공시 • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.
공시 • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.
공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
공시 • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.
공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
공시 • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.
공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
공시 • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.
공시 • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.